Extrinsic hemolytic normocytic anemia: Pathology review

Last updated: November 01, 2022

Extrinsic hemolytic normocytic anemia: Pathology review

Step2 Review

Step2 Review

Introduction to biostatistics
Types of data
Probability
Mean, median, and mode
Range, variance, and standard deviation
Standard error of the mean (Central limit theorem)
Normal distribution and z-scores
Paired t-test
Two-sample t-test
Hypothesis testing: One-tailed and two-tailed tests
One-way ANOVA
Two-way ANOVA
Repeated measures ANOVA
Correlation
Methods of regression analysis
Linear regression
Logistic regression
Spearman's rank correlation coefficient
Mann-Whitney U test
Kappa coefficient
Chi-squared test
Fisher's exact test
Kaplan-Meier survival analysis
Type I and type II errors
Sensitivity and specificity
Positive and negative predictive value
Test precision and accuracy
Incidence and prevalence
Relative and absolute risk
Odds ratio
Attributable risk (AR)
Mortality rates and case-fatality
DALY and QALY
Direct standardization
Indirect standardization
Study designs
Clinical trials
Disease causality
Selection bias
Confounding
Interaction
Prevention
Eczematous rashes: Clinical
Papulosquamous skin disorders: Clinical
Alopecia: Clinical
Hypersensitivity skin reactions: Clinical
Autoimmune bullous skin disorders: Clinical
Blistering skin disorders: Clinical
Hypopigmentation skin disorders: Clinical
Benign hyperpigmented skin lesions: Clinical
Skin cancer: Clinical
Immunodeficiencies: Clinical
Antihistamines for allergies
Glucocorticoids
Advanced cardiac life support (ACLS): Clinical
Supraventricular arrhythmias: Pathology review
Ventricular arrhythmias: Pathology review
Heart blocks: Pathology review
Coronary artery disease: Clinical
Heart failure: Clinical
Syncope: Clinical
Pericardial disease: Clinical
Cardiomyopathies: Clinical
Hypertension: Clinical
Hypercholesterolemia: Clinical
Sympatholytics: Alpha-2 agonists
Adrenergic antagonists: Presynaptic
Adrenergic antagonists: Alpha blockers
Adrenergic antagonists: Beta blockers
ACE inhibitors, ARBs and direct renin inhibitors
Thiazide and thiazide-like diuretics
Calcium channel blockers
cGMP mediated smooth muscle vasodilators
Class I antiarrhythmics: Sodium channel blockers
Class II antiarrhythmics: Beta blockers
Class III antiarrhythmics: Potassium channel blockers
Class IV antiarrhythmics: Calcium channel blockers and others
Lipid-lowering medications: Statins
Lipid-lowering medications: Fibrates
Miscellaneous lipid-lowering medications
Positive inotropic medications
Diabetes mellitus: Clinical
Hyperthyroidism: Clinical
Hypothyroidism and thyroiditis: Clinical
Parathyroid conditions and calcium imbalance: Clinical
Pituitary adenomas and pituitary hyperfunction: Clinical
Hypopituitarism: Clinical
Cushing syndrome: Clinical
Adrenal masses and tumors: Clinical
Adrenal insufficiency: Clinical
MEN syndromes: Clinical
Hyperthyroidism medications
Hypothyroidism medications
Insulins
Hypoglycemics: Insulin secretagogues
Miscellaneous hypoglycemics
Adrenal hormone synthesis inhibitors
Mineralocorticoids and mineralocorticoid antagonists
Esophageal disorders: Clinical
Esophagitis: Clinical
Gastroesophageal reflux disease (GERD): Clinical
Gastroparesis: Clinical
Malabsorption: Clinical
Inflammatory bowel disease: Clinical
Jaundice: Clinical
Cirrhosis: Clinical
Laxatives and cathartics
Antidiarrheals
Acid reducing medications
Fever of unknown origin: Clinical
Fat-soluble vitamin deficiency and toxicity: Pathology review
Anemia: Clinical
Microcytic anemia: Pathology review
Non-hemolytic normocytic anemia: Pathology review
Intrinsic hemolytic normocytic anemia: Pathology review
Extrinsic hemolytic normocytic anemia: Pathology review
Macrocytic anemia: Pathology review
Heme synthesis disorders: Pathology review
Leukemia: Clinical
Lymphoma: Clinical
Thrombocytopenia: Clinical
Bleeding disorders: Clinical
Thrombophilia: Clinical
Myeloproliferative neoplasms: Clinical
Plasma cell disorders: Clinical
Blood products and transfusion: Clinical
Anticoagulants: Heparin
Anticoagulants: Warfarin
Anticoagulants: Direct factor inhibitors
Antiplatelet medications
Thrombolytics
Hematopoietic medications
Ribonucleotide reductase inhibitors
Topoisomerase inhibitors
Platinum containing medications
Anti-tumor antibiotics
Microtubule inhibitors
DNA alkylating medications
Monoclonal antibodies
Antimetabolites for cancer treatment
Infective endocarditis: Clinical
Pneumonia: Clinical
Tuberculosis: Pathology review
Diarrhea: Clinical
Viral hepatitis: Clinical
Urinary tract infections: Clinical
Meningitis, encephalitis and brain abscesses: Clinical
Bites and stings: Clinical
Protein synthesis inhibitors: Aminoglycosides
Antimetabolites: Sulfonamides and trimethoprim
Antituberculosis medications
Miscellaneous cell wall synthesis inhibitors
Protein synthesis inhibitors: Tetracyclines
Cell wall synthesis inhibitors: Penicillins
Miscellaneous protein synthesis inhibitors
Cell wall synthesis inhibitors: Cephalosporins
DNA synthesis inhibitors: Metronidazole
DNA synthesis inhibitors: Fluoroquinolones
Integrase and entry inhibitors
Nucleoside reverse transcriptase inhibitors (NRTIs)
Protease inhibitors
Hepatitis medications
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)
Neuraminidase inhibitors
Herpesvirus medications
Azoles
Echinocandins
Miscellaneous antifungal medications
Anthelmintic medications
Antimalarials
Anti-mite and louse medications
Hypernatremia: Clinical
Hyponatremia: Clinical
Hyperkalemia: Clinical
Hypokalemia: Clinical
Metabolic and respiratory acidosis: Clinical
Metabolic and respiratory alkalosis: Clinical
Toxidromes: Clinical
Medication overdoses and toxicities: Pathology review
Acute kidney injury: Clinical
Chronic kidney disease: Clinical
Nephritic and nephrotic syndromes: Clinical
Renal tubular defects: Pathology review
Renal tubular acidosis: Pathology review
Osmotic diuretics
Carbonic anhydrase inhibitors
Loop diuretics
Potassium sparing diuretics
Stroke: Clinical
Seizures: Clinical
Headaches: Clinical
Hyperkinetic movement disorders: Clinical
Hypokinetic movement disorders: Clinical
Muscle weakness: Clinical
Disorders of consciousness: Clinical
Spinal cord disorders: Pathology review
Sympathomimetics: Direct agonists
Muscarinic antagonists
Cholinomimetics: Direct agonists
Cholinomimetics: Indirect agonists (anticholinesterases)
Anticonvulsants and anxiolytics: Barbiturates
Anticonvulsants and anxiolytics: Benzodiazepines
Nonbenzodiazepine anticonvulsants
Migraine medications
Anti-parkinson medications
Medications for neurodegenerative diseases
Asthma: Clinical
Chronic obstructive pulmonary disease (COPD): Clinical
Diffuse parenchymal lung disease: Clinical
Venous thromboembolism: Clinical
Acute respiratory distress syndrome: Clinical
Pleural effusion: Clinical
Pneumothorax: Clinical
Lung cancer: Clinical
Bronchodilators: Beta 2-agonists and muscarinic antagonists
Bronchodilators: Leukotriene antagonists and methylxanthines
Joint pain: Clinical
Rheumatoid arthritis: Clinical
Seronegative arthritis: Clinical
Systemic lupus erythematosus (SLE): Clinical
Sjogren syndrome: Clinical
Inflammatory myopathies: Clinical
Vasculitis: Clinical
Acetaminophen (Paracetamol)
Non-steroidal anti-inflammatory drugs
Opioid agonists, mixed agonist-antagonists and partial agonists
Antigout medications
Osteoporosis medications
Pregnancy
Routine prenatal care: Clinical
Hypertensive disorders of pregnancy: Clinical
Antepartum hemorrhage: Clinical
Premature rupture of membranes: Clinical
Stages of labor
Abnormal labor: Clinical
Vaginal versus cesarean delivery: Clinical
Postpartum hemorrhage: Clinical
Gestational trophoblastic disease: Clinical
Breastfeeding
Abdominal pain: Clinical
Puberty and Tanner staging
Amenorrhea: Clinical
Contraception: Clinical
Virilization: Clinical
Infertility: Clinical
Vulvovaginitis: Clinical
Sexually transmitted infections: Clinical
Menopause
Abnormal uterine bleeding: Clinical
Ovarian cysts, cancer, and other adnexal masses: Clinical
Endometrial hyperplasia and cancer: Clinical
Cervical cancer: Clinical
Vaginal cancer: Clinical
Vulvar cancer: Clinical
Estrogens and antiestrogens
Progestins and antiprogestins
Androgens and antiandrogens
Aromatase inhibitors
Uterine stimulants and relaxants
Newborn management: Clinical
Neonatal ICU conditions: Clinical
Congenital TORCH infections: Pathology review
Neonatal jaundice: Clinical
Perinatal infections: Clinical
Congenital disorders: Clinical
Congenital heart defects: Clinical
Autosomal trisomies: Pathology review
Miscellaneous genetic disorders: Pathology review
Disorders of carbohydrate metabolism: Pathology review
Disorders of fatty acid metabolism: Pathology review
Glycogen storage disorders: Pathology review
Lysosomal storage disorders: Pathology review
Mood disorders: Clinical
Anxiety disorders: Clinical
Schizophrenia spectrum disorders: Clinical
Dissociative disorders: Clinical
Eating disorders: Clinical
Obsessive compulsive disorders: Clinical
Trauma- and stressor-related disorders: Clinical
Disruptive, impulse-control and conduct disorders: Clinical
Personality disorders: Clinical
Sleep disorders: Clinical
Somatic symptom disorders: Clinical
Sexual dysfunctions: Clinical
Paraphilic disorders: Clinical
Substance misuse and addiction: Clinical
Drug misuse, intoxication and withdrawal: Hallucinogens: Pathology review
Psychiatric emergencies: Pathology review
Preoperative evaluation: Clinical
Postoperative evaluation: Clinical
General anesthetics
Local anesthetics
Neuromuscular blockers
Esophageal surgical conditions: Clinical
Gastrointestinal bleeding: Clinical
Peptic ulcers and stomach cancer: Clinical
Appendicitis: Clinical
Diverticular disease: Clinical
Hernias: Clinical
Bowel obstruction: Clinical
Colorectal cancer: Clinical
Abdominal trauma: Clinical
Anal conditions: Clinical
Gallbladder disorders: Clinical
Pancreatitis: Clinical
Breast cancer: Clinical
Benign breast conditions: Pathology review
Anatomy clinical correlates: Anterior and posterior abdominal wall
Anatomy clinical correlates: Breast
Valvular heart disease: Clinical
Chest trauma: Clinical
Anatomy clinical correlates: Thoracic wall
Anatomy clinical correlates: Heart
Anatomy clinical correlates: Pleura and lungs
Anatomy clinical correlates: Mediastinum
Dizziness and vertigo: Clinical
Thyroid nodules and thyroid cancer: Clinical
Neck trauma: Clinical
Nasal, oral and pharyngeal diseases: Pathology review
Traumatic brain injury: Clinical
Brain tumors: Clinical
Lower back pain: Clinical
Eye conditions: Refractive errors, lens disorders and glaucoma: Pathology review
Eye conditions: Retinal disorders: Pathology review
Eye conditions: Inflammation, infections and trauma: Pathology review
Anatomy clinical correlates: Clavicle and shoulder
Anatomy clinical correlates: Axilla
Anatomy clinical correlates: Arm, elbow and forearm
Anatomy clinical correlates: Wrist and hand
Anatomy clinical correlates: Median, ulnar and radial nerves
Burns: Clinical
Prostate disorders and cancer: Pathology review
Testicular tumors: Pathology review
Kidney stones: Clinical
Renal cysts and cancer: Clinical
Urinary incontinence: Pathology review
PDE5 inhibitors
Peripheral vascular disease: Clinical
Leg ulcers: Clinical
Aortic aneurysms and dissections: Clinical

Transcript

Watch video only

At the family medicine center, two people came in with progressive fatigue.

One of them is a 60 years old named Will whose past medical history included an aortic valve replacement with a mechanical valve due to severe aortic stenosis.

There’s Hanna, a 28 years old female of African descent.

She was diagnosed a year ago with systemic lupus erythematosus, or SLE. CBC is ordered for both people and it shows low hemoglobin with normal mean corpuscular volume, or MCV and reticulocyte count index over 2%.

They also have increased LDH. Now, Will has schistocytes on peripheral blood smear, while Hanna has spherocytes.

Both Will and Hannah are suffering from anemia, which is defined as lower than average levels of hemoglobin, typically below 13.5 g/dL in adult men and below 12.0 g/dL in adult women.

For children, this level varies based on the age. Now, anemias can be broadly grouped into 3 categories based on =MCV, which reflects the volume of an RBC.

So microcytic anemia is where the MCV is lower than 80 fL, normocytic, with an MCV between 80 and 100 fL, and macrocytic, with an MCV larger than 100 fL.

Normocytic anemias can be further classified as hemolytic when there’s increased destruction of RBCs, or hemolysis, and non-hemolytic when there’s decreased production of RBCs from the bone marrow.

When there’s hemolysis, the bone marrow revs up and starts pumping out immature RBCs called reticulocytes, but when there’s a bone marrow problem reticulocyte count is low.

So for your exams, it’s important to know that in hemolytic anemias there’s an increased reticulocyte production index of over 2%, while in non-hemolytic anemias it’s lower than 2%.

Alright, now hemolytic anemias can be classified as intrinsic or extrinsic hemolytic anemias.

In intrinsic hemolytic anemias, RBCs are destroyed because they’re defective, while in extrinsic hemolytic anemias, RBCs are normal but are later destroyed outside the bone marrow.

In this video, let’s focus on extrinsic hemolytic anemias that include autoimmune hemolytic anemia, microangiopathic hemolytic anemia, macroangiopathic hemolytic anemia and infections.

Now, we can divide extrinsic hemolysis into intravascular, meaning RBCs are destroyed within the vasculature, or extravascular, meaning that they are removed by macrophages in the spleen and liver.

Microangiopathic and macroangiopathic hemolytic anemias are intravascular, autoimmune hemolytic anemia is usually extravascular, while infections can cause both intravascular and extravascular.

There are findings that can help identify the type of hemolysis. In intravascular hemolysis, hemoglobin that is released inside the vessels gets bound by a protein called haptoglobin and because they’re removed together, haptoglobin decreases.

Also, when haptoglobin gets overwhelmed, the rest of hemoglobin goes via the blood through the kidneys and into the urine resulting in hemoglobinuria.

Now, when hemoglobin is inside the renal tubules, the cells lining the renal tubules reabsorb hemoglobin.

The heme component of hemoglobin contains iron which is stored as hemosiderin in tubular cells and after a few days, when tubular cells slough into urine, there’s hemosiderinuria. Hemoglobinuria and hemosiderinuria can damage the kidneys causing back pain.

Okay, now in extravascular hemolysis, RBCs are destroyed outside the vessels and so, haptoglobin is normal and there’s no hemoglobin or hemosiderin in the urine.

RBCs are usually destroyed in the spleen causing splenomegaly or the liver causing hepatomegaly.

Alright, now whenever there’s RBC lysis, an intracellular enzyme called lactate dehydrogenase, or LDH, spills out directly into the plasma and builds up in the blood.

Hemoglobin also spills out of the cell and breaks up into globin and heme.

Heme is converted into unconjugated, or indirect, bilirubin which is then taken up by the liver cells and eventually secreted out with bile.

If all of a sudden, your body starts breaking down more RBCs than the liver cells can handle, the excess bilirubin stays in the blood and cause jaundice where the bilirubin deposits in the skin and the eyes, causing them to turn yellow.

Also, when there’s too much bilirubin in the bile, it can form pigmented gallstones.

Some of the bilirubin is converted to urobilin which is what gives urine that yellow color, but if there’s too much of it, the urine becomes a much darker, tea-like color.

Okay, so let’s take a closer look at these different extrinsic hemolytic anemias, starting with autoimmune hemolytic anemia where antibodies and complement are directed against RBCs, leading to their destruction.

It’s like the RBC equivalent of immune thrombocytopenic purpura, or ITP, a disorder where autoantibodies bind to the platelet receptor and cause them to be targeted by immune cells in the spleen for destruction.

In fact, some patients develop both conditions together, and that’s called Evan’s syndrome.

Based on the type of antibodies produced, autoimmune hemolytic anemia can be divided further into IgG, also called warm antibody, hemolytic anemia, and IgM hemolytic anemia, also called cold agglutinin disease.

Now, it’s important to remember the causes, since they might be the best clues for identifying autoimmune hemolytic anemia in the exams.

Warm antibody hemolytic anemia is typically seen in chronic lymphocytic leukemia, or CLL, systemic lupus erythematosus, or SLE, and with the use of antibiotics like penicillins and cephalosporins, sulfa drugs, and the antihypertensive drug, methyldopa.

Cold agglutinin disease is often seen in CLL, Waldenstrom macroglobulinemia, a rare type of malignant lymphoma, and infections like infectious mononucleosis and mycoplasma pneumoniae infections.

Next up is microangiopathic hemolytic anemia that occurs in the small blood vessels and include thrombotic thrombocytopenic purpura, or TTP, hemolytic-uremic syndrome, or HUS, and disseminated intravascular coagulation, or DIC.

In these disorders, there’s excessive clot formation so when normal RBCs flow through these blood vessels, they get banged up and damaged, leading to intravascular hemolysis.

In TTP, there’s a deficiency of ADAMTS-13, a metalloproteinase that breaks Von willebrand factor, a protein needed for the formation of clots and their adhesion to the endothelial lining.

So When there’s not enough ADAMTS-13, there’s excessive clot formation, and these clots end up damaging RBCs.

TTP can be caused by a genetic mutation or it can develop after exposure to antiplatelet medications like ticlopidine and clopidogrel, or chemotherapeutic agents like cyclosporine and gemcitabine.

In some cases it can also be associated with diseases like systemic lupus erythematosus.

Alright, moving onto HUS. Typical HUS, occurs after an infection by a shiga-toxin bacteria.

The most common is Escherichia coli, but others include shigella, and salmonella.

A high yield fact for your exams is that this often occurs in children after an episode of gastroenteritis caused by these bacteria.

The toxins they release destroys colonic epithelial cells, causing bloody diarrhea, and then enters the circulation, where it damages the endothelial cells causing massive release of von willebrand factor and excessive clot formation throughout the body.

Typical HUS has good prognosis. Now, the atypical HUS is not associated with shiga-toxin, may occur at any age, and has a relatively poor prognosis.

It is linked to a genetic mutation in factor H, a protein that controls the complement system. Without it, the complement system goes wild, causing damage to the endothelial cells and excessive clot formation.

Next up is DIC, where there is a massive overactivation of the coagulation system in response to something like sepsis or trauma.

This leads to widespread clotting, organ ischemia, and microangiopathic hemolytic anemia, while at the same time depletes platelets and clotting factors, which paradoxically, leads to bleeding.

Sources

  1. "Kaplan USMLE Step 2 CK Lecture Notes Internal Medicine" Kaplan Medical (2017)
  2. "Robbins Basic Pathology" Elsevier (2017)
  3. "Harrison's Principles of Internal Medicine, Twentieth Edition (Vol.1 & Vol.2)" McGraw-Hill Education / Medical (2018)
  4. "Hemolytic Anemia: Evaluation and Differential Diagnosis" Am Fam Physician (2018)
  5. "Autoimmune hemolytic anemia" Hematology (2018)
  6. "Diagnosis and treatment of autoimmune haemolytic anaemias in adults: a clinical review" Wiener klinische Wochenschrift (2008)
  7. "Hemolytic uremic syndrome" Türk Pediatri Arşivi (2015)
  8. "Haemolytic uremic syndrome: diagnosis and management" F1000Research (2019)
  9. "Management of thrombotic thrombocytopenic purpura: current perspectives" Journal of Blood Medicine (2014)
  10. "Thrombotic microangiopathies: a general approach to diagnosis and management" Canadian Medical Association Journal (2016)
  11. "Relationships between anaemia and parasitic infections in Kenyan schoolchildren: A Bayesian hierarchical modelling approach" International Journal for Parasitology (2008)